logo

For the Inventor, By the Inventor

Montreal, Canada

Theratechnologies Inc.

Calculating rank
USPTO Granted Patents = 29

% Expired Patents = 37.9



Forward Citations = 1,526

Loading Chart...
Loading Chart...

40 inventors (with patents filed for the assignee):

goldMedal Krishna G Peri (10 out of 16 patents)

silverMedal Paul Brazeau (9 out of 15 patents)

bronzeMedal Denis Gravel (8 out of 15 patents)

4.  Thierry Abribat (6 out of 8 patents)

5.  Abdelkrim Habi (6 out of 10 patents)

6.  Soraya Allas (5 out of 5 patents)

7.  Andre De Villers (4 out of 4 patents)

8.  Alcide Chapdelaine (4 out of 4 patents)

9.  Daniel Abran (4 out of 4 patents)

10.  Thierry Abribat (4 out of 6 patents)

11.  Michel Ibea (4 out of 4 patents)

12.  Serge Moffett (3 out of 9 patents)

13.  Sylvain Chemtob (2 out of 13 patents)

14.  Felix Polyak (2 out of 2 patents)

15.  Eryk Thouin (2 out of 3 patents)


Core Competencies:
Peptide Compounds
Growth Hormone
GRF Analogs
Bifunctional Hormones
Wound Closing
Diabetes Treatment
Biological Potency
Intraocular Pressure
Sutureless Closure
Hormone Secretagogues
Stability Formulations
Antagonistic Peptides

29 patents:

1. 9334314 - Peptide compounds derived from melanotransferrin and uses thereof (2016-05-10),
2. 9073963 - [object Object] (2015-07-07),
3. 8871713 - Formulations of growth hormone releasing factor (GRF) molecules with improved stability (2014-10-28),
4. 8822413 - Bifunctional hormone having alpha-MSH activity and natriuretic peptide activity and uses thereof (2014-09-02),
5. 8481489 - GH secretagogues and uses thereof (2013-07-09),
6. 8435945 - GH secretagogues and uses thereof (2013-05-07),
7. 8361964 - Growth hormone releasing factor (GRF) analogs and uses thereof (2013-01-29),
8. 8314066 - GH secretagogues and uses thereof (2012-11-20),
9. 7893025 - Use of growth hormone releasing factor analogs in treating patients suffering from wasting (2011-02-22),
10. 7538185 - Glucagon-like peptide-1 analogs with long duration of action (2009-05-26),
11. 7521530 - [object Object] (2009-04-21),
12. 7414029 - Antagonistic peptides of prostaglandin E2 receptor subtype EP4 (2008-08-19),
13. 7316997 - GH secretagogues and uses thereof (2008-01-08),
14. 7094761 - Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions (2006-08-22),
15. 7067488 - Modified GLP-1 peptides with increased biological potency (2006-06-27),
Company Overview
Theratechnologies Inc. is a biopharmaceutical company based in Montreal, Canada, specializing in the development of innovative therapies for unmet medical needs. The organization focuses on advancing treatments primarily in the fields of endocrinology and oncology, with a commitment to improving the quality of life for patients. Through its research and development efforts, Theratechnologies aims to address significant health challenges, leveraging cutting-edge science to create effective solutions in the biopharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

29 Patents

#38 in Montreal

#481 in Canada

#22,581 in the World

Montreal, CA
Montreal, Canada

Theratechnologies Inc.

Forward Citations = 1,526

40 inventors:

goldMedal Krishna G Peri (10 out of 16 patents)

silverMedal Paul Brazeau (9 out of 15 patents)

bronzeMedal Denis Gravel (8 out of 15 patents)

4.  Thierry Abribat (6 out of 8 patents)

5.  Abdelkrim Habi (6 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Theratechnologies Inc.. Retrieved from https://idiyas.com/company/theratechnologies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…